ShopSpell

Long Shot: Vaccines for National Defense [Hardcover]

$51.99       (Free Shipping)
100 available
  • Category: Books (History)
  • Author:  Hoyt, Kendall
  • Author:  Hoyt, Kendall
  • ISBN-10:  0674061586
  • ISBN-10:  0674061586
  • ISBN-13:  9780674061583
  • ISBN-13:  9780674061583
  • Publisher:  Harvard University Press
  • Publisher:  Harvard University Press
  • Pages:  320
  • Pages:  320
  • Binding:  Hardcover
  • Binding:  Hardcover
  • Pub Date:  01-Jan-2012
  • Pub Date:  01-Jan-2012
  • SKU:  0674061586-11-MPOD
  • SKU:  0674061586-11-MPOD
  • Item ID: 104792251
  • Seller: ShopSpell
  • Ships in: 2 business days
  • Transit time: Up to 5 business days
  • Delivery by: Nov 22 to Nov 24
  • Notes: Brand New Item. Not shipped to AK, HI, APO, FPO, AE.

At the turn of the twenty-first century, the United States contended with a state-run biological warfare program, bioterrorism, and a pandemic. Together, these threats spurred large-scale government demand for new vaccines, but few have materialized. A new anthrax vaccine has been a priority since the first Gulf War, but twenty years and a billion dollars later, the United States still does not have one. This failure is startling.

Historically, the United States has excelled at responding to national health emergencies. World War II era programs developed ten new or improved vaccines, often in time to meet the objectives of particular military missions. Probing the history of vaccine development for factors that foster timely innovation, Kendall Hoyt discovered that vaccine innovation has been falling, not rising, since World War II. This finding is at odds with prevailing theories of market-based innovation and suggests that a collection of nonmarket factors drove mid-century innovation. Ironically, many late-twentieth-century developments that have been celebrated as a boon for innovationthe birth of a biotechnology industry and the rise of specialization and outsourcingundercut the collaborative networks and research practices that drove successful vaccine projects in the past.

Hoyts timely investigation teaches important lessons for our efforts to rebuild twenty-first-century biodefense capabilities, especially when the financial payback for a particular vaccine is low, but the social returns are high.

I've had the good fortune to know past leaders in vaccine development. I have also observed the present model from an orchestra seat since the mid-80s. The technology is now a given. Long Shot challenges us to find the leadership and the will to rediscover the way ahead for orphan medical countermeasures.At a time of continuing concern regarding bioterrorism and emerging diseases, the development of new vaccines is essential. Long Shot, an o
Add Review